Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) Financial Performance & Income Statement Overview
Review Vertex Pharmaceuticals Incorporated (VRTX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Vertex Pharmaceuticals Incorporated (VRTX) Income Statement & Financial Overview
View the income breakdown for Vertex Pharmaceuticals Incorporated VRTX across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $2.77B | $2.91B | $2.77B | $2.65B |
| Cost of Revenue | $363.00M | $423.40M | $392.60M | $371.90M |
| Gross Profit | $2.41B | $2.49B | $2.38B | $2.27B |
| Gross Profit Ratio | $0.87 | $0.85 | $0.86 | $0.86 |
| R&D Expenses | $979.70M | $998.70M | $875.90M | $5.42B |
| SG&A Expenses | $396.40M | $377.60M | $371.80M | $372.20M |
| Operating Expenses | $1.78B | $1.46B | $1.26B | $5.79B |
| Total Costs & Expenses | $2.14B | $1.89B | $1.66B | $6.16B |
| Interest Income | $120.90M | $128.20M | $132.20M | $156.50M |
| Interest Expense | $3.00M | $2.80M | $7.50M | $9.90M |
| Depreciation & Amortization | $48.40M | $46.50M | $53.20M | $54.00M |
| EBITDA | $781.80M | $1.18B | $1.28B | -$3.33B |
| EBITDA Ratio | $0.28 | $0.41 | $0.46 | -$1.26 |
| Operating Income | $630.10M | $1.03B | $1.12B | -$3.51B |
| Operating Income Ratio | $0.23 | $0.35 | $0.40 | -$1.33 |
| Other Income/Expenses (Net) | $100.30M | $110.50M | $107.80M | $123.50M |
| Income Before Tax | $730.40M | $1.14B | $1.22B | -$3.39B |
| Income Before Tax Ratio | $0.26 | $0.39 | $0.44 | -$1.28 |
| Income Tax Expense | $84.10M | $223.50M | $178.70M | $202.40M |
| Net Income | $646.30M | $913.00M | $1.05B | -$3.59B |
| Net Income Ratio | $0.23 | $0.31 | $0.38 | -$1.36 |
| EPS | $2.52 | $3.55 | $4.05 | -$13.92 |
| Diluted EPS | $2.49 | $3.50 | $4.01 | -$13.92 |
| Weighted Avg Shares Outstanding | $256.90M | $257.50M | $258.00M | $258.10M |
| Weighted Avg Shares Outstanding (Diluted) | $259.50M | $260.50M | $261.00M | $258.10M |
Over the past four quarters, Vertex Pharmaceuticals Incorporated demonstrated steady revenue growth, increasing from $2.65B in Q2 2024 to $2.77B in Q1 2025. Operating income reached $630.10M in Q1 2025, maintaining a consistent 23% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $781.80M, reflecting operational efficiency. Net income dropped to $646.30M, with EPS at $2.52. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan